Cervical Cancer, Condylomata Acuminata
Conditions
Keywords
human papillomavirus vaccine
Brief summary
This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged 18-45 years old.
Interventions
BIOLOGICALHPV Vaccine,270μg/1.0ml
HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
BIOLOGICALPlacebo
Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Sponsors
Xiamen Innovax Biotech Co., Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Xiamen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Health women aged between 18 and 45 years. 2. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations. 3. Able to comply with the requests of the study. 4. Written informed consent obtained from the participants. 5. Axillary temperature not higher than 37.0°C 6. Non-pregnant women verified by a urine pregnancy test.
Exclusion criteria
1. Pregnant or breastfeeding or plan to be pregnant within 7 months. 2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period. 3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment. 4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine or plan to use within 7 months. 5. Administration of any attenuated live vaccines within 21 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination. 6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination. 7. Having the plan to participate another clinical trial during the study period. 8. Received another HPV vaccine. 9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response). 10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain. 11. Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years. 12. Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al. 13. Diagnosed coagulant function abnormality or blood coagulation disorder. 14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years. 15. Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or hve a tendency to commit suicide in the past 5 years. 16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody) | month 7 | To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level on day 0 (before the 1st dose) and one month after dose 3 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Solicited local adverse reactions | During the 7-day (Day 0-6) period following each vaccination | Solicited local adverse reactions occurred within 7 days after each vaccination; |
| Solicited systematic adverse reactions | During the 7-day (Day 0-6) period following each vaccination | Solicited systematic adverse reactions occurred within 7 days after each vaccination; |
| Unsolicited adverse events | Within 30 days (Day 0-29) after any vaccination | Unsolicited adverse reactions occurred within 30 days after each vaccination; |
| Serious adverse events | throughout the study period, an average of 7 months | Serious adverse events occurred throughout the study; |
Other
| Measure | Time frame | Description |
|---|---|---|
| Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific IgG antibody) | month 7 | To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level on day 0 (before the 1st dose) and one month after dose 3 |
| Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations in a immunogenicity subgroup at Months 1,2 and 7 (type specific neutralizing antibody and IgG antibody) | month 1,2 and 6 | To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing and IgG antibody level of a immunogenicity subgroup at month 1,2 and 6. |
Countries
China
Outcome results
None listed